(Lymphoma) Opdivo (Nivolumab) Approved for Pediatric Patients with Hodgkin Lymphoma in Japan
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- October 4, 2021
- 1 min read
On September 27, 2021, Ono Pharmaceutical announced that Opdivo (nivolumab), an immune checkpoint inhibitor, received approval in Japan for use in pediatric patients aged 1 year and older with refractory or relapsed Hodgkin lymphoma. This marks the first approval of an immune checkpoint inhibitor for pediatric cancer patients in Japan.
Approximately 1,720 cases of Hodgkin lymphoma are diagnosed annually in Japan, of which approximately 70 are pediatric patients. Adult patients had previously been approved to receive Opdivo treatment.
Source: https://www.sankei.com/article/20210927-O4FZHJV26BK25FRPKLROEKTGO4/
Lymphoma | Immunotherapy | Pediatric | Nivolumab
-
Immunotherapy
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4